Search

Displaying results 7801 - 7810 of 10000 in total
  1. Drug

    AGS-16C3F

    go.drugbank.com/drugs/DB17551
    Investigational

    AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate.

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Chamaecyparis obtusa whole

    go.drugbank.com/drugs/DB16632
    Investigational

    Mixtures: Forest Hand Sanitizer, Forest Hand Sanitizer
  3. Drug

    Zodasiran

    go.drugbank.com/drugs/DB17626
    Investigational

    It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).[L45869]

    Categories: Nucleic Acids, Nucleotides, and Nucleosides
  4. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  5. Drug

    Turmeric

    go.drugbank.com/drugs/DB14276
    ApprovedInvestigational

    It is not an approved drug.

  6. Drug

    Purslane

    go.drugbank.com/drugs/DB14327
    Approved

    It is not an approved drug.

  7. Drug

    Lufepirsen

    go.drugbank.com/drugs/DB14915
    Investigational

    CODA-001 is under investigation in clinical trial NCT01165450 (Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects).

  8. Drug

    Coleneuramide

    go.drugbank.com/drugs/DB14932
    Investigational

    Coleneuramide is under investigation in clinical trial NCT00307749 (Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy).

  9. Drug

    LY-3200882

    go.drugbank.com/drugs/DB16064
    Investigational

    LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).

  10. Drug

    Olodanrigan

    go.drugbank.com/drugs/DB16266
    Investigational

    Olodanrigan is under investigation in clinical trial NCT03297294 (Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)).